Rebus Holdings Past Earnings Performance
Past criteria checks 2/6
Rebus Holdings's earnings have been declining at an average annual rate of -86.4%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-86.4%
Earnings growth rate
-91.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Rebus Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | 1 | 0 | 0 |
| 31 Mar 23 | 0 | -1 | 0 | 0 |
| 31 Dec 22 | 0 | -1 | 0 | 0 |
| 30 Sep 22 | 0 | -2 | 0 | 1 |
| 30 Jun 22 | 0 | 4 | 1 | 1 |
| 31 Mar 22 | 0 | 23 | 0 | 0 |
| 31 Dec 21 | 0 | 3 | 1 | 0 |
| 30 Sep 21 | 0 | -4 | 1 | 0 |
| 30 Jun 21 | 0 | -8 | 1 | 0 |
| 31 Mar 21 | 0 | -26 | 1 | 0 |
| 31 Dec 20 | 0 | -6 | 0 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | -2 | 0 | 0 |
| 31 Mar 20 | 0 | -2 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | 2 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | 0 | 1 | 0 |
| 31 Dec 18 | 0 | 0 | 1 | 0 |
| 30 Sep 18 | 0 | -6 | 1 | 1 |
| 30 Jun 18 | 0 | -10 | 1 | 1 |
| 31 Mar 18 | 0 | -11 | 1 | 1 |
| 31 Dec 17 | 0 | -13 | 2 | 2 |
| 30 Sep 17 | 0 | -11 | 2 | 1 |
| 30 Jun 17 | 0 | -6 | 2 | 1 |
| 31 Mar 17 | 0 | -6 | 2 | 1 |
| 31 Dec 16 | 0 | -4 | 2 | 1 |
| 30 Sep 16 | 0 | -3 | 3 | 1 |
| 30 Jun 16 | 0 | -3 | 3 | 2 |
| 31 Mar 16 | 0 | -5 | 3 | 2 |
| 31 Dec 15 | 0 | -6 | 4 | 2 |
| 30 Sep 15 | 0 | -6 | 4 | 3 |
| 30 Jun 15 | 0 | -7 | 4 | 3 |
| 31 Mar 15 | 0 | -7 | 3 | 3 |
| 31 Dec 14 | 0 | -7 | 3 | 4 |
| 30 Sep 14 | 0 | -7 | 3 | 4 |
| 30 Jun 14 | 0 | -7 | 3 | 4 |
| 31 Mar 14 | 0 | -6 | 3 | 4 |
Quality Earnings: RBSH has high quality earnings.
Growing Profit Margin: Insufficient data to determine if RBSH's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RBSH has become profitable over the past 5 years.
Accelerating Growth: RBSH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RBSH had negative earnings growth (-86.4%) over the past year, making it difficult to compare to the Biotechs industry average (16.6%).
Return on Equity
High ROE: RBSH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.